Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Futibatinib

Review the clinical trials studying futibatinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-5 of 5

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Location: 16 locations
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Status: Active
Location: 10 locations
Futibatinib in Combination with Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients who are Ineligible for Cisplatin-based Therapy
Status: Active
Location: 3 locations
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov